Capricor Therapeutics Inc (CAPR.OQ)
CAPR.OQ on NASDAQ Stock Exchange Capital Market
3.54USD
19 Jun 2019
3.54USD
19 Jun 2019
Change (% chg)
-- (--)
-- (--)
Prev Close
$3.54
$3.54
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
4,925
4,925
52-wk High
$15.70
$15.70
52-wk Low
$2.60
$2.60
About
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the... (more)
Overall
| Beta: | 1.80 |
| Market Cap(Mil.): | $12.28 |
| Shares Outstanding(Mil.): | 3.47 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CAPR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 104.93 | 37.25 |
| EPS (TTM): | -4.59 | -- | -- |
| ROI: | -133.53 | 7.73 | 12.15 |
| ROE: | -196.70 | 8.25 | 16.99 |
U.S. drug developer Capricor places Duchenne drug trial on hold
Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.
UPDATE 1-U.S. drug developer Capricor places Duchenne drug trial on hold
Dec 26 Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.
Capricor places Duchenne drug trial on hold
Dec 26 Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy, a muscle-wasting disorder.
Estimates